vs
Side-by-side financial comparison of Commercial Bancgroup, Inc. (CBK) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.
Commercial Bancgroup, Inc. is the larger business by last-quarter revenue ($23.1M vs $13.7M, roughly 1.7× Xilio Therapeutics, Inc.). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs 41.3%, a 34.4% gap on every dollar of revenue.
Commercial Bancgroup, Inc.CBKEarnings & Financial Report
Commercial Bancgroup, Inc. operates as a U.S. regional bank holding company that provides a full suite of retail and commercial banking products and services to individual consumers, small and medium-sized businesses, and local institutional clients. Its core offerings include deposit accounts, lending solutions, wealth management, and tailored financial advisory services for regional markets.
Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.
CBK vs XLO — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $23.1M | $13.7M |
| Net Profit | $9.5M | $10.4M |
| Gross Margin | — | — |
| Operating Margin | — | -86.5% |
| Net Margin | 41.3% | 75.7% |
| Revenue YoY | — | — |
| Net Profit YoY | 9.7% | 179.1% |
| EPS (diluted) | $0.69 | $-3.74 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $23.1M | — | ||
| Q4 25 | $23.5M | $13.7M | ||
| Q3 25 | $22.8M | $19.1M | ||
| Q2 25 | — | $8.1M | ||
| Q1 25 | — | $2.9M |
| Q1 26 | $9.5M | — | ||
| Q4 25 | $9.9M | $10.4M | ||
| Q3 25 | $9.5M | $-16.3M | ||
| Q2 25 | — | $-15.8M | ||
| Q1 25 | — | $-13.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | -86.5% | ||
| Q3 25 | 53.8% | -10.1% | ||
| Q2 25 | — | -177.7% | ||
| Q1 25 | — | -472.7% |
| Q1 26 | 41.3% | — | ||
| Q4 25 | 42.2% | 75.7% | ||
| Q3 25 | 41.4% | -85.4% | ||
| Q2 25 | — | -196.0% | ||
| Q1 25 | — | -452.7% |
| Q1 26 | $0.69 | — | ||
| Q4 25 | $0.72 | $-3.74 | ||
| Q3 25 | $0.77 | $-0.11 | ||
| Q2 25 | — | $-0.16 | ||
| Q1 25 | — | $-0.18 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $137.5M |
| Total DebtLower is stronger | $118.2M | — |
| Stockholders' EquityBook value | — | $35.3M |
| Total Assets | $2.3B | $154.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $137.5M | ||
| Q3 25 | $154.8M | $103.8M | ||
| Q2 25 | — | $121.6M | ||
| Q1 25 | — | $89.1M |
| Q1 26 | $118.2M | — | ||
| Q4 25 | $166.8M | — | ||
| Q3 25 | $100.1M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | $35.3M | ||
| Q3 25 | $245.2M | $-8.1M | ||
| Q2 25 | — | $7.1M | ||
| Q1 25 | — | $10.7M |
| Q1 26 | $2.3B | — | ||
| Q4 25 | $2.3B | $154.7M | ||
| Q3 25 | $2.2B | $133.7M | ||
| Q2 25 | — | $133.8M | ||
| Q1 25 | — | $103.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.41× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-2.0M |
| Free Cash FlowOCF − Capex | — | $-2.1M |
| FCF MarginFCF / Revenue | — | -15.3% |
| Capex IntensityCapex / Revenue | — | 0.7% |
| Cash ConversionOCF / Net Profit | — | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $-2.0M | ||
| Q3 25 | $28.0M | $-17.5M | ||
| Q2 25 | — | $-14.5M | ||
| Q1 25 | — | $29.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | $-2.1M | ||
| Q3 25 | $26.5M | — | ||
| Q2 25 | — | $-14.9M | ||
| Q1 25 | — | $29.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | -15.3% | ||
| Q3 25 | 115.8% | — | ||
| Q2 25 | — | -184.0% | ||
| Q1 25 | — | 988.3% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.7% | ||
| Q3 25 | 6.7% | 0.0% | ||
| Q2 25 | — | 5.0% | ||
| Q1 25 | — | 0.8% |
| Q1 26 | — | — | ||
| Q4 25 | — | -0.19× | ||
| Q3 25 | 2.96× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CBK
| Net Interest Income | $20.5M | 89% |
| Noninterest Income | $2.6M | 11% |
XLO
Segment breakdown not available.
